

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5805092

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
CELLTECH R&D LTD.	10/24/2012
RECEIVING PARTY DATA	
Name:	UCB PHARMA, S.A.
Street Address:	60, ALLEE DE LA RECHERCHE
City:	BRUSSELS
State/Country:	BELGIUM
Postal Code:	B-1070
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16674003
CORRESPONDENCE DATA	
Fax Number:	(352)372-5800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	3523758100
Email:	fce@slepatents.com
Correspondent Name:	FRANK C. EISENSCHENK, PH.D.
Address Line 1:	P.O. BOX 142950
Address Line 4:	GAINESVILLE, FLORIDA 32614-2950
ATTORNEY DOCKET NUMBER:	UCB.107D1
NAME OF SUBMITTER:	FRANK C. EISENSCHENK, PH.D.
SIGNATURE:	/FRANK C. EISENSCHENK/
DATE SIGNED:	11/05/2019
Total Attachments: 1	
source=ExecAsgn-Cell2UCB#page1.tif	

ASSIGNMENT FROM CELLTECH R&D LTD.
TO
UCB PHARMA, S.A.


In consideration of one dollar (\$1.00) and other good and valuable consideration, CELLTECH R&D LTD., having a place of business at 208 Bath Road, Slough SL1 3WE, Berkshire, United Kingdom, sells and assigns to UCB PHARMA, S.A., having a place of business at 60, Allée de la Recherche, B-1070 Brussels, Belgium, its successors and assigns, the entire right, title and interest throughout the world in and to the improvements in:

“Process for Obtaining Antibodies”
U.S. Patent Application Serial No. 13/576,980, filed August 3, 2012,

and in and to said application and all patents (foreign and domestic) which may be granted therefor and thereon, and all divisions, reissues, continuations and extensions thereof (foreign and domestic), and CELLTECH R&D LTD. authorizes and requests the Commissioner of Patents and Trademarks to issue all patents on said improvements or resulting therefrom to said UCB PHARMA, S.A., as assignee of the entire interest; and it agrees that it will sign all lawful papers, execute all divisional, continuing and reissue applications, and make all rightful oaths to aid said UCB PHARMA, S.A., its successors, assigns and nominees, to obtain and enforce proper protection for said improvements in all countries.

Executed this 24 day of OCTOBER, 2012.

CELLTECH R&D LTD.

By: 
Printed Name: MARK GWYN HARDY
Title: DIRECTOR

WITNESS:

Signature: 

Printed Name: RAVI GILL

Date: 24/10/12.